Dr James (Jamie) T Kelly

Jamie completed his PhD in virology at the University of Leeds in 2015, focusing on virus entry and antiviral capsid-binding compounds for Enterovirus A71, under the supervision of Prof Nicola Stonehouse and Prof David Rowlands. He briefly worked as a postdoctoral researcher in the same group. 

In 2016, Jamie joined The Pirbright Institute to work with Dr Toby Tuthill in the Picornavirus Molecular Biology Group, studying the role of picornavirus VP4 in cell entry. In 2018, he transitioned to the Viral Glycoproteins group with Dr Dalan Bailey, investigating ISGs and small molecule inhibitors of RSV cell-cell fusion. In 2021, he returned to the Picornavirus Molecular Biology Group to explore the use of Rhinovirus VP4 as a vaccine. 

In 2023, Jamie began his role as a Research Co-Investigator, focusing on the role antiviral restriction factors play in determining host range and species-jumping in livestock viral diseases, using FMDV as a model.